Market Overview

UPDATE: Bank of America Downgrades Dr. Reddy's Laboratories to Neutral on Modest Outlook


Bank of America downgraded Dr. Reddy's Laboratories (NYSE: RDY) from Buy to Neutral with a $36.72 price objective.

Bank of America noted, "Following recent outperformance (vs BSE Healthcare), we downgrade DRL from Buy to Neutral with a revised PO of Rs1975. This factors (1) higher mkt share from recent US launches, reflected in slight increase in core profit estimates, partially offset by (2) sharp cut in exclusivities driving reduction in NPV to Rs25 (vs Rs70 earlier). We expect multiples to be capped due to modest growth prospects (12% profit CAGR), below historic growth and peers."

Dr Reddy's Laboratories closed at $35.76 on Thursday.

Latest Ratings for RDY

Sep 2019UpgradesUnderperformOutperform
Jun 2019Initiates Coverage OnEqual-Weight
May 2019DowngradesOverweightEqual-Weight

View More Analyst Ratings for RDY
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings


Related Articles (RDY)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Bank of America Downgrades Gold Fields Limited to Neutral Following Unbundling, New Plans

UPDATE: Morgan Stanley Upgrades H.J. Heinz Company to Equal-Weight Following Deal